Thomas C. Carr

Gilead Sciences, Inc.'s (NASDAQ: GILD) strong sales of its hepatitis C drug will help it beat expectations when the company posts fourth-quarter earnings later today, an analyst said. "Gilead should beat earnings expectations handily" on strength in sales of its Sovaldi hepatitis...